Abstract
AbstractPulmonary drug delivery by portable inhalers is the gold standard in lung disease therapy. An increasing focus on environmentally friendly inhalation currently spurs the development of propellant-free devices. However, the absence of propellants in the drug creates a need for suitable sealing systems that can ensure the pathogenic safety of devices. Traditionally, liquid drug inhalers incorporate a spray nozzle and a separate check valve. Here we show a fully integrated MEMS-based spray system for aqueous drug solutions and demonstrate its bacterial safety. The device comprises a thin silicon membrane with spray orifices, which self-seal against a compliant parylene valve seat underneath. This sealing system prevents bacterial ingrowth in its default closed state, while actuation lifts the membrane from the valve seat upon pressurization and sprays an inhalable aerosol from the nozzles. To seal against bacterial contamination effectively, we found that a contact force between the valve seat and the membrane (featuring the spray nozzles) is needed. In our testing, both self-sealing and an otherwise identical unvalved version of the spray chip can be bacterially safe in continued use when thoroughly cleaned of excess fluids and subjected to low bacterial loads for brief periods. However, when directly exposed to $$10^{7}$$
10
7
CFU/ml of our test organism Citrobacter rodentium for 24 h, unvalved systems become contaminated in nearly 90% of cases. In contrast, self-sealing spray chips reduced contamination probability by 70%. This development may enable preservative-free drug formulations in portable inhalers that use propellant-free aqueous drug solutions.
Funder
SHL Group AB
Royal Institute of Technology
Publisher
Springer Science and Business Media LLC
Subject
Molecular Biology,Biomedical Engineering
Reference31 articles.
1. V.V. Agnihotri, C.V. Pardeshi, S.J. Surana. Chapter 11 - A current update on advanced drug delivery devices for nasal and pulmonary administration. In: Chappel E (ed) Drug Delivery Devices and Therapeutic Systems, Developments in Biomedical Engineering and Bioelectronics, Academic Press, pp 213–245 (2021). https://doi.org/10.1016/B978-0-12-819838-4.00003-1
2. ATCC, Citrobacter rodentium Schauer et al. (ATCC 51459) (2021). https://www.atcc.org/products/51459
3. W. Baiker, Respimat® success story: Boehringer Ingelheim invests EUR 72 million in production capacity in Ingelheim (2015). https://www.boehringer-ingelheim.pt/press-release/respimatr-success-story-boehringer-ingelheim-invests-eur-72-million-production
4. K.L. Barnes, R. Clifford, S.T. Holgate, D. Murphy, P. Comber, E. Bell, Bacterial contamination of home nebuliser. Br. Med. J. (Clin. Res. Ed.) 295(6602), 812 (1987)
5. M. Birkhoff, Delivering on the growing need for topical preservative free ophthalmic treatments. ONdrugDelivery Magazine Issue 104 (Jan 2020):pp 8–12 (2020)
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Advances in soft mist inhalers;Expert Opinion on Drug Delivery;2023-07-10